This is the first instalment of my three-part investigative report on the Chinese-made Innova lateral flow test. Vast sums of UK taxpayers’ money have been paid to a California start-up for tests that have failed to stand up to scrutiny.
…Innova Medical Group, the company benefiting from the UK Government’s huge testing contract, is owned by the private equity group Pasaca Capital which was founded by a Chinese investment banker, the enigmatic Dr Charles Huang, in 2017. It has been revealed to be the single largest recipient of the Department of Health’s Covid contracts after signing a £496million deal to supply LFTs last year. An earlier contract with Innova cost the taxpayer £107million.
I had no choice but to speak out against lockdowns. As a public-health scientist with decades of experience working on infectious-disease outbreaks, I couldn’t stay silent. Not when basic principles of public health are thrown out of the window. Not when the working class is thrown under the bus. Not when lockdown opponents were thrown to the wolves. There was never a scientific consensus for lockdowns. That balloon had to be popped.
…Ultimately, lockdowns protected young low-risk professionals working from home – journalists, lawyers, scientists, and bankers – on the backs of children, the working class and the poor.
Doctors are now being told to look out for signs of the most common type of stroke following the Oxford coronavirus vaccine, after three British patients were admitted to hospital and one died.
Two women in their 30s and a man in his 40s suffered ischaemic strokes after having the vaccine.
Previous reports of rare blood clots from the jab have specifically involved cerebral venous thrombosis – a rare form of stroke caused by the blockage of specific veins.
A woman in her 30s has died from a stroke after the Oxford/AstraZeneca Covid vaccination caused a blood clot to form in an artery in her brain.
The patient, a 35-year-old Asian woman, went to hospital six days after her vaccine appointment, and died two weeks after being admitted following “extensive hemorrhaging”.
THE influence of the Bill & Melinda Gates Foundation (GF) extends right into the heart of the British medical and science establishment. It has been funding British companies, charities, universities and public bodies for almost 25 years.
The open letter states that “a good society cannot be created by an obsessive focus on a single cause of ill-health” and states all restrictions should be lifted in June on the final date in Prime Minister Boris Johnson’s ‘roadmap’ out of lockdown. Masks should no longer be worn by schoolchildren after May 17, say the scientists – and they warn the damage to society will be too great if the current Covid control measures continue beyond the June roadmap date.
Vaccine passports should also be scrapped along with mass community testing, they say.
Instead, the government should focus on targeted testing, creating better incentives for staying home if ill and basic hygiene measures, such as handwashing and surface cleaning.
Signatories (in alphabetical order)
Professor Ryan Anderson, Translational Science, Medicines Discovery Catapult
Dr Colin Axon, Mechanical Engineering, Brunel University
Professor Anthony Brookes, Genomics and Bioinformatics, University of Leicester
Professor Jackie Cassell, FFPH, Deputy Dean, Brighton and Sussex Medical School
Professor Angus Dalgleish, FRCP, FRCPath, FMedSci, Oncology, St George’s, University of London
Professor Robert Dingwall, FAcSS, HonMFPH, Sociology, Nottingham Trent University
Professor Sunetra Gupta, Theoretical Epidemiology, University of Oxford
Professor Carl Heneghan, MRCGP, Centre for Evidence Based Medicine, University of Oxford
Professor Mike Hulme, Human Geography, University of Cambridge.
Dr John Lee – formerly Pathology, Hull York Medical School
Professor David Livermore, Medical Microbiology, University of East Anglia.
Professor Paul McKeigue Genetic Epidemiology and Statistical Genetics, University of Edinburgh
Professor David Paton, Industrial Economics, University of Nottingham
Emeritus Professor Hugh Pennington, CBE, FRCPath, FRCP (Edin), FMedSci, FRSE, Bacteriology, University of Aberdeen
Dr Gerry Quinn, Biomedical Sciences, University of Ulster
Dr Roland Salmon, MRCGP, FFPH, former Director of the Communicable Disease Surveillance Centre (Wales).
Emeritus Professor John Scott, CBE, FRSA, FBA, FAcSS, Sociology, University of Essex
Professor Karol Sikora, FRCR, FRCP, FFPM, Medicine, University of Buckingham
Professor Ellen Townsend, Psychology, University of Nottingham
Dr Chao Wang, Health & Social Care Statistics, Kingston University and St George’s, University of London,
Professor John Watkins, Epidemiology, Cardiff University
Professor Lisa White, Modelling and Epidemiology, University of Oxford.
A year ago, there was no evidence that lockdowns would protect older high-risk people from Covid-19. Now there is evidence. They did not.
With so many Covid-19 deaths, it is obvious that lockdown strategies failed to protect the old. Holding the naïve belief that shutting down society would protect everyone, governments and scientists rejected basic focused protection measures for the elderly. While anyone can get infected, there is more than a thousand-fold difference in the risk of death between the old and the young. The failure to exploit this fact about the virus led to the biggest public health fiasco in history.
A study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer and Moderna vaccines as they are for the AstraZeneca vaccine that was produced with the university’s help. According to the study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine. The risk of getting CVT is much higher for those who get COVID-19 — 39 in a million patients — than it is for those for get vaccinated. AstraZeneca’s vaccine use has been halted or limited in many countries on blood clot concerns.
The latest figures from the Office for National Statistics (ONS) show that 23 per cent of coronavirus deaths registered are now people who have died “with” the virus rather than “from” an infection.
This means that, while the person who died will have tested positive for Covid, that was not the primary cause of their death recorded on the death certificate.
All UK spontaneous reports received between 04/01/21 and 05/04/21 for COVID-19 vaccine Oxford University/AstraZeneca
The researchers added the gene for the coronavirus spike protein to another virus called an adenovirus. Adenoviruses are common viruses that typically cause colds or flu-like symptoms. The Oxford-AstraZeneca team used a modified version of a chimpanzee adenovirus, known as ChAdOx1. It can enter cells, but it can’t replicate inside them.
QCovid is an evidence-based model that uses a range of factors such as age, sex, ethnicity and existing medical conditions to predict risk of death or hospitalisation from COVID-19.
It provides nuanced information on people’s risk of serious illness due to COVID-19 and has the potential to help patients and doctors reach a shared understanding of risk.
It is a ‘living’ risk prediction model which will be updated regularly as our understanding of COVID-19 increases and more data become available.
The risk calculator can be found at the link below. You will be asked to accept the license terms but it does not ask for any personally identifiable information.
- Vaccine produced by a partnership between a University of Oxford research institute, Vaccitech, and AstraZeneca, does not need to be stored at freezing temperatures.
- Cheaper and easier to produce than the high-efficacy vaccines produced by BioNTech-Pfizer and Moderna.
- The price of AstraZeneca’s shares dropped on the news, and an analysis from an investment bank concluded, “We believe that this product will never be licensed in the US.”
- A closer look at the the Oxford-AstraZeneca trials reveals some very shaky science.
- Cherry-picked the data
- Dosing issues
- Opaque planning and data analysis procedures
- Age group selection
Data presented by the Government’s chief advisers to justify a second national lockdown in England has been “mathematically proven” to be incorrect, an Oxford University professor has said.
Antibody tests may be missing large numbers of people who contracted Covid-19 because they don’t work for people who had a mild infection, new research from Oxford University suggests.
A study of more than 9,000 healthcare workers suggested significant numbers of people were getting ‘negative’ test results, despite probably having had the virus.
As professor of epidemiology at Yale School of Public Health, I have authored over 300 peer-reviewed publications and currently hold senior positions on the editorial boards of several leading journals. I am usually accustomed to advocating for positions within the mainstream of medicine, so have been flummoxed to find that, in the midst of a crisis, I am fighting for a treatment that the data fully support but which, for reasons having nothing to do with a correct understanding of the science, has been pushed to the sidelines. As a result, tens of thousands of patients with COVID-19 are dying unnecessarily. Fortunately, the situation can be reversed easily and quickly.
I am referring, of course, to the medication hydroxychloroquine. When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, especially when given in combination with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.
- As a result, tens of thousands of patients with COVID-19 are dying unnecessarily.
- An inexpensive and be highly effective treatment, especially when given early: Hydroxychloroquine in combination with the antibiotics azithromycin or doxycycline and zinc.
- The article, “Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis” was published in the American Journal of Epidemiology (AJE). It analyzed five studies, demonstrating clear benefits and safety of this treatment.
- Other studies include:
- an additional 400 high-risk patients treated by Dr. Vladimir Zelenko, with zero deaths;
- four studies totaling almost 500 high-risk patients treated in nursing homes and clinics across the U.S., with no deaths;
- a controlled trial of more than 700 high-risk patients in Brazil, with significantly reduced risk of hospitalization and two deaths among 334 patients treated with hydroxychloroquine;
- and another study of 398 matched patients in France, also with significantly reduced hospitalization risk.
- “Natural experiments:” northern Brazil state of Pará used hydroxychloroquine to reduce deaths.
- Hydroxychloroquine has shown major success when used early in high-risk people but, as one would expect for an antiviral, much less success when used late in the disease course.
- Delays in waiting before starting the medications can reduce their efficacy.
- FDA concerns about the drug did not announce is that these adverse events were generated from tens of millions of patient uses of hydroxychloroquine for long periods of time, often for the chronic treatment of lupus or rheumatoid arthritis.
- The harms are minuscule compared to the mortality occurring right now in inadequately treated high-risk COVID-19 patients.
The new Oxford study released by Royal Society and British Academy does not prove face coverings work. It is a policy document masquerading as an investigation into face coverings.
The Mayor Of London claims new evidence supports the use of face coverings as effective in reducing the spread of COVID-19. He cites a University of Oxford study that claims: “face masks and coverings work – act now.“
The study, from Oxford’s Leverhulme Centre for Demographic Science, is freely available for download from The Royal Society website. Nevertheless, we doubted that many people would take time to verify the claims so we took a look. What did we find?
The bulk of study is in fact an investigation into policies and behavioural factors behind face mask usage. Only a small section is dedicated to analysing the effectiveness of cloth face coverings and even this provides nothing new. Further, rather than performing randomised controlled trials (RCTs), which form the highest level of evidence in medical science, this report simply looked at existing research.
From this existing research, the authors forced a conclusion that ‘face masks and coverings work’ but with some very important caveats:
- The tests were carried out in medical and lab settings, not within the community.
- There were other factors that contributed to the masks’ effectiveness.
- The conclusions were based on small studies.
The study limitations can be found in the document appendix, table A5.1.
What can we conclude from the release of this study?
It seems evidence for universal masking of healthy people in the community so flimsy that sleight of hand is needed in order to push public acceptance.
Update 19 July 2020:
A Spiked Online article published on 16 July, The government has lost control, draws the same conclusions:
The Royal Society published, on 26 June, a ‘rapid review of the science of the effectiveness of different face-mask types’ – a dense, 37-page tract which made the case for face masks. It was neither peer-reviewed nor opened to wide expert and public debate before being used to argue for policy.
…the hasty assembling of research articles in support of a policy position is not science, and demanding that the government introduce new ‘taboos’ is naive and clumsy social engineering, not careful examination of the facts.
Prolonged periods of lockdown cocooning the public from germs could leave people dangerously vulnerable to new viruses, a leading epidemiologist has warned.
Sunetra Gupta, professor of theoretical epidemiology at the University of Oxford, fears intense social distancing could actually weaken immune systems because people are not exposed to germs and so do not develop defences that could protect them against future pandemics.
The Recovery trial has steadfastly ignored Professor Didier Raoult and a string of countries that have implemented his protocol, early use of HCQ with Azythromycin in safe doses, despite the fact that, after treating 3,737 patients — the single largest study in the world —Raoult has lost only 0.6 per cent, while Horby and Landray are presiding over carnage —a fatality rate of 25 per cent.
- The Recovery trial has steadfastly ignored Professor Didier Raoult in the early use of HCQ with Azythromycin in safe doses.
- Raoult has lost only 0.6 per cent, while Horby and Landray are presiding over carnage —a fatality rate of 25 per cent.
- Landray admitted to an investigative journalist at FranceSoir ‘these are quite high doses to… have a chance of killing the virus.’ Or killing the patient.
- Recovery is not the only trial delivering dangerously elevated doses of HCQ to Covid patients. Dosage in the international Solidarity trial was four times greater than the dose being used in India.
- WHO has been working for years with Gilead Sciences trying to get the pharmaceutical company’s lacklustre drug Remdesivir to show efficacy at curing first Ebola, with poor results, and now Covid-19.
- Landray revealed Gilead pays scientists 20 to 50 times more to conduct a clinical trial than Horby and Landray were paid to conduct the Recovery trial.
- Horby is the executive director of the International Severe Acute Respiratory and Emerging Infection Consortium which received 4.5 million pounds for research into vaccines.
- Horby established the Epidemic Research Group which is promised up to 14 million pounds from AstraZeneca and Zuckerberg/Chan of Facebook fame for the development of a Covid-19 vaccine which is being trialled by Oxford University.
- AstraZeneca is interested in merging with Gilead Sciences, which, if it went through, would create the biggest Big Pharma ever.
- Horby and Landray have announced that dexamethasone, a low-cost steroid which is also being tested has reduced the mortality rate of Covid-19 patients on ventilators from a scandalous 41 per cent to a still appalling 32 per cent.
- Raoult has pointed out that in his hospital, of the 0.6 per cent who die, a mere 16 per cent were in ICU
- In Britain, where almost 42,000 people have died of Covid, the only thing randomised, controlled trials have achieved, is to blind people to the evidence that 40,000 of those deaths could have been avoided.
A coronavirus vaccine professor at Oxford University says there is now ‘little chance’ of proving if it works due to low transmission rates in the UK.
Professor Sarah Gilbert, leading the University of Oxford vaccine trial, said that when Covid-19 transmission was high, lockdown was imposed to bring the rate down.
But since then rates have dropped, and the trial relies on a sufficient number of volunteers to have been exposed to the virus to see whether a vaccine protects them or not.